MINOX SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

MINOXIDIL

제공처:

LABORATOIRE RIVA INC.

ATC 코드:

D11AX01

INN (International Name):

MINOXIDIL, TOPICAL

복용량:

20MG

약제 형태:

SOLUTION

구성:

MINOXIDIL 20MG

관리 경로:

TOPICAL

패키지 단위:

250ML

처방전 유형:

OTC

치료 영역:

MISC. SKIN AND MUCOUS MEMBRANE AGENTS

제품 요약:

Active ingredient group (AIG) number: 0114429001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2022-09-29

제품 특성 요약

_MINOX (Minoxidil Topical Solution) _
_Page 1 of 33_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
MINOX
Minoxidil Topical Solution
20 mg/mL (2% w/v)
USP
Hair Regrowth Treatment
THIS PRODUCT IS FOR MEN ONLY
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.labriva.com
Date of Initial Authorization:
August 19, 1996
Date of Revision:
August 4, 2022
Submission Control Number: 263345
_MINOX (Minoxidil Topical Solution) _
_Page 2 of 33_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
.......................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.4
Administration...................................................................................................
5
4.5
Missed Dose
......................................................................................................
6
5
OVERDOSAGE
.............................................................................................................
6
6
DOSAGE FORMS, STRENGTHS, COMPOSI